Contact Us
Contact Us
Contact Us

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
05/12/2019Appendix 3BDownload
05/12/2019Appendix 3Y-Dr Daniel TillettDownload
05/12/2019Prof Borje Andersson to Chair Clinical Advisory BoardDownload
03/12/2019Race releases video of 2019 AGM presentationDownload
26/11/2019Replacement Appendix 3Y-Dr Bill GarnerDownload
26/11/2019Appendix 3Y-Dr John CullityDownload
26/11/2019Appendix 3Y-Dr Daniel TillettDownload
26/11/2019Appendix 3Y-Chris NtoumenopoulosDownload
26/11/2019Appendix 3B-Issue of OptionsDownload
26/11/2019Appendix 3Y-Dr Bill GarnerDownload
1  2  3  4  5  6  7  8  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2019 Race Oncology. Website By Multiplier